Von Hippel–Lindau disease

Rare genetic disorder causing tumors in multiple organs

von Hippel–Lindau disease
Synonyms	Familial cerebello-retinal angiomatosis, VHL syndrome
Pronounce	N/A
Field	N/A
Symptoms	Headaches, dizziness, visual disturbances, limb weakness, balance problems, hypertension
Complications	Vision loss, hearing impairment, renal failure, metastatic cancer, neurological deficits
Onset	Typically young adulthood (20–40 years)
Duration	Lifelong
Types	N/A
Causes	Mutation in the VHL tumor suppressor gene on chromosome 3p25.3
Risks	Family history, autosomal dominant inheritance
Diagnosis	Genetic testing, imaging (MRI, CT), ophthalmologic examination
Differential diagnosis	Neurofibromatosis type 2, multiple endocrine neoplasia (MEN), polycystic kidney disease
Prevention	Genetic counseling, regular surveillance screenings
Treatment	Surgical removal of tumors, radiation therapy, targeted medical therapies
Medication	Antihypertensives, targeted therapy for associated malignancies
Prognosis	Variable; lifelong management required, favorable with early detection and treatment
Frequency	1 in 36,000 individuals worldwide
Deaths	Primarily due to complications such as metastatic cancer or renal failure

Von Hippel–Lindau disease (VHL disease) is a rare, autosomal dominant genetic disorder characterized by the formation of tumors and fluid-filled cysts in multiple organs throughout the body. Tumors commonly occur in the central nervous system, kidneys, pancreas, adrenal glands, and eyes.

Signs and symptoms

Slit lamp photograph showing retinal detachment in von Hippel–Lindau disease.

Symptoms of VHL disease depend on tumor location, size, and organ involvement. Common presentations include:

• Neurological symptoms:
  • Headaches
  • Dizziness
  • Problems with balance and walking (ataxia)
  • Limb weakness and numbness
  • Hearing impairment (due to endolymphatic sac tumors)

• Visual symptoms:
  • Vision loss or blurring
  • Retinal detachment
  • Visual disturbances due to retinal hemangioblastoma

• Systemic symptoms:
  • High blood pressure (hypertension) from adrenal tumors (pheochromocytoma)
  • Abdominal pain and pancreatic dysfunction from pancreatic cysts or tumors
  • Hematuria (blood in urine), flank pain, or renal dysfunction from renal cell carcinoma

Associated conditions

VHL disease predisposes patients to develop multiple tumor types, including:

• Hemangioblastomas (vascular tumors affecting the brain, spinal cord, and retina)
• Retinal hemangioblastoma (formerly called retinal angiomas)
• Renal cell carcinoma
• Pheochromocytoma (adrenal gland tumors causing high blood pressure)
• Pancreatic cysts and serous cystadenomas
• Endolymphatic sac tumor (rare inner-ear tumors causing hearing and balance issues)
• Bilateral papillary cystadenomas of the epididymis (men) or the broad ligament of the uterus (women)

Genetics

Von Hippel–Lindau disease results from a mutation in the VHL tumor suppressor gene located on the short arm of chromosome 3 (3p25.3). The disease follows an autosomal dominant inheritance pattern, meaning an affected individual has a 50% chance of passing the mutation to offspring.

The VHL gene normally functions to suppress abnormal cell growth by regulating cellular oxygen sensing. Mutation or deletion of this gene leads to uncontrolled cellular proliferation and tumor formation.

Diagnosis

Diagnosis is established through clinical criteria, family history, and genetic testing:

• Clinical evaluation: Detailed neurological, ophthalmological, and systemic examinations
• Imaging studies:
  • MRI (brain, spine) to identify hemangioblastomas
  • CT/MRI abdomen to evaluate kidneys, pancreas, and adrenal glands
• Genetic testing: Confirms VHL gene mutation, guides familial screening

Differential diagnosis

Conditions that must be distinguished from VHL disease include:

• Neurofibromatosis type 2 (bilateral vestibular schwannomas)
• Multiple endocrine neoplasia (MEN) syndromes
• Polycystic kidney disease
• Tuberous sclerosis complex

Management

There is no cure for VHL disease; management is focused on early detection, monitoring, and prompt treatment of tumors:

• Surgical removal of symptomatic tumors or tumors at risk of malignancy
• Radiation therapy for inaccessible or recurrent central nervous system tumors
• Medical management: Control of hypertension (particularly due to pheochromocytomas), targeted therapies for renal cell carcinoma
• Regular surveillance screenings:
  • Annual ophthalmologic examinations for retinal hemangioblastomas
  • Periodic MRI scans of brain and spine
  • Routine screening of kidneys, pancreas, and adrenal glands through imaging and laboratory tests

Prognosis

Prognosis depends on timely diagnosis, effective tumor management, and lifelong surveillance. With early detection and intervention, patients can have relatively normal life expectancy. Delayed diagnosis or inadequate management increases risk of severe complications, including vision loss, neurological deficits, metastatic renal cell carcinoma, and premature death.

Epidemiology

Von Hippel–Lindau disease is rare, with an estimated incidence of approximately 1 in 36,000 individuals globally. It affects men and women equally and typically becomes clinically apparent in early adulthood, though age of onset can vary widely.

History

VHL disease is named after ophthalmologist Eugen von Hippel, who first described retinal hemangioblastomas in 1904, and neuropathologist Arvid Lindau, who detailed central nervous system involvement and familial inheritance in 1927.

Research

Current research is focused on:

• Improved genetic and molecular characterization of VHL mutations
• Novel targeted therapies, including drugs targeting hypoxia-inducible factors (HIF) regulated by VHL
• Gene therapy approaches to correct VHL gene defects

See also

• Hemangioblastoma
• Pheochromocytoma
• Renal cell carcinoma
• Genetic counseling

External links

• VHL Disease – Genetic and Rare Diseases Information Center (GARD)
• VHL Alliance – Patient Advocacy Group
• Von Hippel–Lindau Disease – National Cancer Institute